Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review.
NSCLC
concomitant drugs
immunotherapy
opioids
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
30 Dec 2022
30 Dec 2022
Historique:
received:
29
11
2022
revised:
24
12
2022
accepted:
26
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
9
1
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) represent one of the most effective treatments for patients with cancer. As their activity relies on host immune system reactivity, the role of concomitant medications such as corticosteroids and antibiotics has been extensively evaluated. Preclinical data suggest that opioids may influence the immune system. a systematic literature revision was performed using specific keywords on the major search engines. Two authors analysed all the studies and provided a selection of the following inclusion and exclusion criteria, respectively: 1. data collection of patients older than 18 years old affected by solid tumours; 2. description of ICIs efficacy in terms of PFS, OS, TTF, and ORR; 3. concomitant ICIs-opioids treatment and 1. language different from English; 2. not pertinent analyses. 523 studies were analysed, and 13 were selected and included in our series. A possible negative interaction between oral opioids and ICIs efficacy was observed. Most evidence was retrospective, and studies were heterogeneous. Even if oral opioids seem to impact negatively on ICIs efficacy in cancer patients, to date there is not sufficient evidence to avoid their prescription in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) represent one of the most effective treatments for patients with cancer. As their activity relies on host immune system reactivity, the role of concomitant medications such as corticosteroids and antibiotics has been extensively evaluated. Preclinical data suggest that opioids may influence the immune system.
METHODS
METHODS
a systematic literature revision was performed using specific keywords on the major search engines. Two authors analysed all the studies and provided a selection of the following inclusion and exclusion criteria, respectively: 1. data collection of patients older than 18 years old affected by solid tumours; 2. description of ICIs efficacy in terms of PFS, OS, TTF, and ORR; 3. concomitant ICIs-opioids treatment and 1. language different from English; 2. not pertinent analyses.
RESULTS
RESULTS
523 studies were analysed, and 13 were selected and included in our series. A possible negative interaction between oral opioids and ICIs efficacy was observed. Most evidence was retrospective, and studies were heterogeneous.
CONCLUSIONS
CONCLUSIONS
Even if oral opioids seem to impact negatively on ICIs efficacy in cancer patients, to date there is not sufficient evidence to avoid their prescription in this population.
Identifiants
pubmed: 36611575
pii: healthcare11010116
doi: 10.3390/healthcare11010116
pmc: PMC9818864
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Pain Rep. 2021 Mar 2;7(2):e995
pubmed: 35261931
Curr Pain Headache Rep. 2012 Aug;16(4):307-13
pubmed: 22644902
J Transl Med. 2021 Mar 23;19(1):119
pubmed: 33757546
Eur J Cancer. 2021 Jan;142:18-28
pubmed: 33212418
J Immunol. 1979 Sep;123(3):1068-70
pubmed: 224107
Egypt J Immunol. 2014;21(2):33-47
pubmed: 25812351
Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):790-799
pubmed: 34446261
Cancer. 1997 Oct 15;80(8 Suppl):1588-94
pubmed: 9362426
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33154150
Int Immunopharmacol. 2010 Sep;10(9):1149-52
pubmed: 20609402
Eur J Cancer. 2021 Nov;157:474-484
pubmed: 34649118
BMJ Support Palliat Care. 2020 Dec 8;:
pubmed: 33293293
J Immunol. 2013 Nov 1;191(9):4640-7
pubmed: 24068670
Mucosal Immunol. 2016 Nov;9(6):1418-1428
pubmed: 26906406
Clin Transl Oncol. 2020 Sep;22(9):1481-1490
pubmed: 31919759
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Thorac Cancer. 2021 Jul;12(13):1983-1994
pubmed: 33990133
J Pain Palliat Care Pharmacother. 2007;21(4):69-76
pubmed: 18032321
Cancers (Basel). 2022 Apr 30;14(9):
pubmed: 35565382
Br J Anaesth. 2013 Jul;111(1):105-11
pubmed: 23794652
Ther Adv Med Oncol. 2021 Mar 15;13:17588359211000591
pubmed: 33796151
J Neuroimmunol. 2013 Dec 15;265(1-2):43-50
pubmed: 24090653
J Clin Oncol. 2016 Feb 10;34(5):436-42
pubmed: 26644526
Sci Rep. 2021 Dec 2;11(1):23331
pubmed: 34857829
Lancet. 2019 Nov 16;394(10211):1807-1815
pubmed: 31645288
Br J Anaesth. 2021 Jul;127(1):65-74
pubmed: 33966891
J Neuroimmune Pharmacol. 2011 Dec;6(4):442-65
pubmed: 21789507
Int J Mol Sci. 2020 Feb 22;21(4):
pubmed: 32098316
Int J Clin Oncol. 2018 Jun;23(3):410-420
pubmed: 29516216
Front Immunol. 2019 Dec 12;10:2914
pubmed: 31921173
Cancer. 2015 Oct 1;121(19):3507-14
pubmed: 26207518
BMC Pulm Med. 2022 Nov 21;22(1):431
pubmed: 36411438
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Pain. 2015 Oct;156(10):1835-1844
pubmed: 26181303
Br J Clin Pharmacol. 2022 Jul;88(7):3114-3131
pubmed: 35229890
J Clin Oncol. 2014 Jun 1;32(16):1677-90
pubmed: 24799483
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005180
pubmed: 15654708